JUPITER, Fla., May 3, 2012 /PRNewswire/ -- BioRestorative Therapies, Inc.("BRT" or the "Company") (OTCQB: BRTX), a life sciences company focused on adult stem cell-based therapies, announced today that the latest version of its stem cell disc delivery device, which is to be used in the treatment of bulging and herniated discs, has shown improvements when compared to earlier versions.
The first generation of the device had shown the potential to reduce disc bulges and avoid lower back surgery with a simple injection procedure. The latest generation has shown improvements, and testing of the device will continue to be done to obtain improved disc penetration and steering for optimal cell placement.
The patent-pending delivery device to be used by medical practitioners is a specifically designed needle/catheter delivery system that will inject cells directly into the annular tear that is causing the bulge or herniation.
On April 11, 2012, the Company announced the closing of its licensing agreement with Regenerative Sciences, Inc. pursuant to which BRT was granted, among other things, the exclusive right to license and sell the stem cell delivery device worldwide.
Mark Weinreb, CEO of BRT, commented, "The delivery device's novel design and unique capability of delivering cells, specifically where they are most effective, is a necessary component of the treatment regimen. As our disc restoration program advances and we receive all necessary approvals, we look forward to easing the pain experienced by back and disc pain sufferers."
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc.'s goal is to become a leader in developing medical procedures using cell and tissue protocols, primarily involving a patient's own stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. The Company has obtained a license for the adult stem cell treatments of disc and spine conditions, including bulging and herniated discs. The technology is an advanced stem cell injection procedure, using the patient's own cells, that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the legs and feet. The Company has also launched a technology that involves the use of a brown fat cell-based therapeutic/aesthetic program, known as the ThermoStem Program. The ThermoStem Program will focus on treatments for obesity, weight loss, diabetes, hypertension, other metabolic disorders and cardiac deficiencies and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders. The Company also offers facial creams and products under the Stem Pearls® brand.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
KCSA Strategic Communications
Philip Carlson / Josh Dver
+1 212.896.1233 / +1 212.896.1239
email@example.com / firstname.lastname@example.org
SOURCE BioRestorative Therapies, Inc.